Business

Novartis Commits $23 Billion to U.S. Expansion Amid Shifting Global Pharma Landscape

The timing of the announcement comes as the pharmaceutical industry anticipates the introduction of U.S. tariffs that could affect global supply chains. Although drugmakers were temporarily exempt from the sweeping tariffs unveiled last week by the Trump administration, further measures are expected.

• By Newsdesk
• Washington DC
• Apr 11, 2025

Business

Swiss pharmaceutical giant Novartis has unveiled a sweeping $23 billion investment plan to bolster its manufacturing and research capabilities across the United States, signaling a strategic shift as the global drug industry braces for potential trade policy changes and supply chain realignments.

The five-year investment initiative will see Novartis construct seven new facilities and expand several existing sites, with the goal of ensuring domestic production of all key medications it markets in the U.S. These span therapeutic areas from oncology to cardiovascular diseases. The company’s expansion is expected to generate close to 1,000 direct jobs, with an additional 4,000 created across its supply chain and local communities.

“This commitment is driven by a pro-innovation policy and regulatory environment in the U.S. that empowers us to pursue the next generation of medical breakthroughs,” said Vas Narasimhan, CEO of Novartis. “We are strengthening our U.S. footprint to ensure resilience, innovation, and patient access.”

The timing of the announcement comes as the pharmaceutical industry anticipates the introduction of U.S. tariffs that could affect global supply chains. Although drugmakers were temporarily exempt from the sweeping tariffs unveiled last week by the Trump administration, further measures are expected.

Novartis is also investing in reshoring the production of active pharmaceutical ingredients (APIs), a move that addresses the industry’s longstanding dependence on suppliers in China and India. The company plans to deepen its capabilities in advanced manufacturing, particularly in radioligand therapy — a precision cancer treatment — with new production facilities in Florida and Texas and expansions in Indiana, New Jersey, and California.

A major highlight of the investment plan is the establishment of a $1.1 billion research and development institute in San Diego, marking its second major U.S. R&D hub alongside its existing facility in the Boston area.

Novartis joins a growing list of pharmaceutical heavyweights reinforcing their U.S. presence. Eli Lilly recently pledged $27 billion for expansion, Johnson & Johnson committed over $55 billion to build four new factories, and AstraZeneca announced a $3.5 billion investment late last year.

Narasimhan emphasized the company’s long-term outlook remains robust despite external uncertainties. “We are fully confident in our financial guidance, including achieving a core operating margin of at least 40 percent by 2027,” he said.

This bold investment underscores a broader industry trend toward localization and innovation — priorities that are reshaping the future of pharmaceutical production in the United States.

(With inputs from Financial Times)